Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clovis CEO's Rough Guide To European Launches

Executive Summary

Local knowledge on the regulatory and commercial fronts is an absolute must to succeed in Europe, Patrick Mahaffy tells Scrip a couple of months after the firm's PARP inhibitor Rubraca hit the German market.

You may also be interested in...



GSK Embraces PARP Promise With Tesaro Buy

The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon. 

Clovis In Pole Position To Be First PARP For Prostate Cancer

Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel